The European Medicines Agency (EMA) has endorsed (1 July 2020) a joint statement on prioritisation of COVID-19 clinical trials published by the International Coalition of Medicines Regulatory Authorities (ICMRA).
In the statement, regulators outlined the key characteristics of clinical trials
most likely to generate the conclusive evidence needed to accelerate potential treatments and vaccines against COVID-19. It also sets out actions that should be taken in relation to testing repurposed treatments. The statement also urges investigators to make findings and evidence quickly and widely available to benefit the global research community.
Read more at the EMA website.